Embracing the Future: Eliminating Sutures in Tissue Regeneration for Faster Healing
In a groundbreaking development, Tissium, a spin-off from MIT and Harvard, has received FDA authorisation for commercial use of its novel suture-free biopolymer platform. This platform, at the heart of Tissium's success, is poised to transform the landscape of tissue repair and fixation.
The flagship product, COAPTIUM Connect, is a game-changer in nerve repair. This fully bioabsorbable, flexible polymer sleeve repairs severed peripheral nerves without the need for sutures or staples. Activated by blue light, COAPTIUM Connect conforms and bonds atraumatically to tissues, restoring full movement and pain-free recovery in patients with nerve injuries. This FDA authorisation (De Novo) in mid-2025 marks a significant milestone, demonstrating clinical success in this area.
Beyond nerve repair, Tissium's biopolymer platform shows great adaptability, extending to cardiovascular and abdominal tissues. The company currently has six products in development, including clinical trials for hernia repair and forthcoming cardiovascular applications. The polymers are programmable, allowing control over properties such as degradation rate and mechanical strength, enabling customised solutions for different medical needs.
Tissium's innovative 3D printing process facilitates scalable manufacturing of implantable medical devices from the same polymeric platform. This technology could make it easier to expand and create various implantable medical devices, opening up a world of possibilities.
The success of Tissium's technology is not limited to nerve repair. In a recent trial involving 12 patients, all regained full flexion and extension of their injured digits, and reported no pain 12 months after surgery. This non-traumatic, sutureless solution offers surgeons a new solution for tissue repair, based on biopolymer technology first developed at MIT.
Tissium's founders, including Maria Pereira, Jeff Karp, and Robert Langer, are eager to apply their programmable platform to other areas beyond the current scope. If the technology works in one application, there's a strong intuition that it could work in many others. The team is encouraging people in the medical field to reach out if they think their platform could improve the standard of care.
As Tissium continues to push the boundaries of what's possible in tissue repair, it's clear that this pioneering company is set to revolutionise the medical world. With its FDA authorisation and expanding clinical trials, Tissium is poised to make a significant impact in the lives of many patients.
- The faculty at MIT and Harvard have seen a groundbreaking development with Tissium, as its novel suture-free biopolymer platform received FDA authorization for commercial use.
- This platform, central to Tissium's success, demonstrates the potential to transform the ecosystem of tissue repair and fixation in the health and wellness sector.
- The flagship product, COAPTIUM Connect, is revolutionizing nerve repair, using a fully bioabsorbable, flexible polymer sleeve that repairs severed peripheral nerves without sutures or staples.
- COAPTIUM Connect, activated by blue light, conforms and bonds atraumatically to tissues, restoring full movement and pain-free recovery in patients with nerve injuries.
- The mid-2025 FDA De Novo authorisation marks a significant milestone, showcasing clinical success in the field of nerve repair.
- Beyond nerve repair, Tissium's biopolymer platform shows great adaptability, extending to cardiovascular and abdominal tissues, with six products in development.
- The team's programmable polymers allow control over properties such as degradation rate and mechanical strength, enabling customized solutions for various medical needs.
- Tissium's innovative 3D printing process facilitates scalable manufacturing of implantable medical devices, opening up a world of possibilities in technology and medicine.
- The founders of Tissium, Maria Pereira, Jeff Karp, and Robert Langer, are eager to explore applications beyond current medical-conditions, believing in the technology's potential to improve the standard of care.
- As the team at Tissium keeps pushing the boundaries of tissue repair, they are positioned to bring about significant breakthroughs in the commercialization of patented technologies, further advancing the science of health and space exploration.
